Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)
RATIONALE: Pegaspargase may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with pegaspargase may kill more cancer cells.
PURPOSE: This clinical trial is studying the side effects of giving pegaspargase together with combination chemotherapy and to see how well it works in treating patients with newly diagnosed high-risk acute lymphoblastic leukemia.
Drug: daunorubicin hydrochloride
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate
Radiation: prophylactic cranial irradiation
|Study Design:||Primary Purpose: Treatment|
|Official Title:||Intensified PEG-Asparaginase in High Risk Acute Lymphoblastic Leukemia (ALL): A Pilot Study|
- Feasibility and safety of intensified pegaspargase therapy [ Designated as safety issue: Yes ]
|Study Start Date:||February 2009|
|Estimated Primary Completion Date:||March 2015 (Final data collection date for primary outcome measure)|